|Bid||212.45 x 1200|
|Ask||214.00 x 800|
|Day's Range||211.45 - 214.13|
|52 Week Range||197.47 - 306.08|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||20.61|
|Earnings Date||Apr 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||284.73|
Back in 2016, Bank of America/Merrill Lynch issued a report that compared the performance of growth stocks to value stocks over a 90-year period (1926-2015). The results showed that value stocks were the superior choice (17% annual average return, versus 12.6% for growth stocks), albeit no investors are complaining with annual average returns of 12.6% or 17%. With lending rates at or near historic lows and the Federal Reserve remaining highly accommodative, growth stocks have run circles around value stocks for more than a decade.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.
Since the March 23 bear market low, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite are up a cool 70%, 76%, and 104%, respectively. Many of the same theses that bulls have extolled for years continue to drive Bitcoin's ascent. For example, fans still view its 21 million token limit as a hedge against the long-term devaluation of the U.S. dollar as the money supply increases.